Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court
HERTFORDSHIRE, England and PITTSBURGH, /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone® 40 mg/mL dosing patents are invalid as obvious. The Federal Circuit also affirmed today the final written decisions issued by the Patent Trial and Appeal Board in three inter partes reviews filed by Mylan related to the same patents.
These were the last remaining patent infringement cases Mylan was defending in the U.S. relating to Glatiramer Acetate Injection 40mg/mL. Today's decisions are important milestones as we continue to focus our efforts on meeting the needs of multiple sclerosis patients in the U.S. with Mylan's more affordable treatment option.
The invalidated patents are U.S. Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries, Ltd.
Copaxone® is the most prescribed MS treatment for relapsing forms of MS in the U.S. with brand sales for the 20 mg/mL dose of approximately $527 million and for the 40 mg/mL dose of approximately $2.86 billion for the 12 months ending Aug. 31, 2018, according to IQVIA. Approximately 400,000 individuals in the U.S. have MS and relapsing MS accounts for 85% of initial MS diagnoses.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mylan-prevails-in-copaxone-40mgml-litigation-against-teva-in-us-appellate-court-300730245.html
SOURCE Mylan N.V.
Company Codes: NASDAQ-NMS:MYL